HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Staff banner

Staff Profile: Wei Sun

Wei Sun, Ph.D.

Scientist, Pharmacology (Contractor), Therapeutics for Rare and Neglected Diseases

Division of Pre-Clinical Innovation

National Center for Advancing Translational Sciences

National Institutes of Health

E-mail Wei Sun

Biography

Wei Sun is a scientist for the Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs at NCATS. He came to the Center in 2012 from the University of North Carolina at Chapel Hill. Sun worked with Wei Zheng, Ph.D., on pre-clinical drug development for treatment of Niemann-Pick disease type C and malaria. Sun received his Ph.D. in pharmaceutical sciences from the University of North Carolina at Chapel Hill, where he worked on assay development and mechanisms of actions for small molecule regulators of the ADP-ribosylation factors’ GTPase-activating proteins.

Research Topics

In his current position, Sun supports the biology and pharmacology components of TRND and BrIDGs projects to advance drug candidates from pre-clinical stages to investigational new drug and clinical investigations. These projects include small molecule and biologic therapeutics. Collaborating with researchers both within and outside of NIH, he leads assay development and high-throughput screens of several drug repurposing projects, such as those focused on Ebola and multidrug-resistant bacteria. Sun is also interested in combining chemical biology and proteomic approaches to identify novel protein targets for small molecule drugs.

Selected Publications

  1. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.
  2. Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens.
  3. ERK and β-arrestin interaction: a converging point of signaling pathways for multiple types of cell surface receptors.
  4. Chemical signatures and new drug targets for gametocytocidal drug development.
  5. δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.